CORESTEMCHEMON Inc.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
As of 2026-10-09, CORESTEMCHEMON Inc. has 1 Korean MFDS drug approval, 18 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Products & technology
- Neuronata-RALS (amyotrophic lateral sclerosis) treatment
Regulatory approvals
data.go.kr1 Korean MFDS drug approvals · 2021
- MFDS drugNeuronata-R®inj.2021-08-27Drug · Prescription · Approval202106193
Clinical trials
data.go.kr7 MFDS clinical trial authorisations · 2015–2024 (Phase 1 6 · Phase 3 1)
- Phase 1CE211NS212024-06-05
5 trial sites
- Phase 1뉴로나타-알주2022-08-05
2 trial sites
- Phase 1CS10BR052018-04-20
1 trial site
- Phase 1CS20AT042017-07-17
1 trial site
- Phase 1CS10BR052016-06-09
1 trial site
- Phase 1CS20AT042015-05-06
1 trial site
- Phase 3뉴로나타-알주2015-04-17
5 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Not yet recruiting · 2026-12 · NCT07595965
Phase 1 · Completed · 2022-11 · NCT06676423
Phase 3 · Completed · 2021-02 · NCT04745299
Completed · 2018-08 · NCT04495582
Phase 1 · Completed · 2018-04 · NCT03265444
Completed · 2017-11 · NCT04522505
Phase 1 · Completed · 2017-05 · NCT03174587
Phase 1/2 · Completed · 2011-02 · NCT01363401
R&D and key agreements
Source: DART corporate disclosure2세대(차세대) 줄기세포치료제 · 희귀·난치성질환 · 기초연구·공정자동화기술 연구개발중 · Developing new stem cell therapies for rare and intractable diseases, with basic research on second-generation stem cell therapies and process automation technology under way.
Key disclosures
KRX KIND via OpenDARTShow 3 more events
Publications
PubMed · affiliation-matched- Evaluation of subchronic oral dose toxicity of Antrodia camphorata mycelium powder in rodents as a novel food source.
BMC complementary medicine and therapies · 2026-06 · Shim WY, Park ES, Jang SI 외 3
- Subchronic oral toxicity and genotoxicity of Aurantii Fructus Immaturus water extract.
Regulatory toxicology and pharmacology : RTP · 2026-02 · An SY, Song SW, Heo HS 외 7
- Plasma extracellular vesicles-derived MicroRNAs as potential biomarkers in idiopathic pulmonary fibrosis.
Respiratory research · 2026-01 · Lee JK, Park JK, Nam JY 외 1
- Automated spermatogenic staging in periodic acid-Schiff-stained testes of Sprague-Dawley rats using a deep learning model for normal and atrophied tissues.
PloS one · 2026-01 · Kim DM, Rho JH, Wee SY 외 1
- Combined Repeated-Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test of Calcium Nitrate Tetrahydrate in Sprague Dawley Rats.
Toxics · 2025-09 · Eom JW, Kang HI, Lee JH 외 5
- Ninety-day repeated oral toxicity and genetic toxicity studies of powderized Aurantii Fructus Immaturus.
Regulatory toxicology and pharmacology : RTP · 2025-09 · An S, Kim S, Song SW 외 8
- Immunophenotypic and Transcriptomic Analysis of Peripheral Blood Mononuclear Cells in Bullous Pemphigoid.
Annals of dermatology · 2025-08 · Choi J, Nam JY, Kim MS 외 3
- Estimating treatment effect on timed 25-foot walk in multiple sclerosis: A systematic review and meta-analysis.
Multiple sclerosis and related disorders · 2025-05 · Lee J, Yuk M, Youn J 외 10
- KoCVAM-led validation of KeraSkin™ Phototoxicity Assay for inclusion in OECD TG 498.
ALTEX · 2025-01 · Kang NH, Park CE, Kim SH 외 5
- Single and repeated-dose toxicity studies by intravaginal administration of Lactobacillus plantarum ATG-K2 powder in female rats.
Toxicological research · 2025-01 · Kang JH, Kang MS, Kim SD 외 4
Show 8 more publications
- Ameliorating Effect of Fermented Perilla frutescens on Sleep Deprivation-Induced Cognitive Impairment Through Antioxidant and BDNF Signaling in Mice.
Nutrients · 2024-12 · Seo CR, Lee BK, Jee HJ 외 4
- Post-symptomatic administration of hMSCs exerts therapeutic effects in SCA2 mice.
Stem cell research & therapy · 2024-11 · Kim S, Sharma C, Hong J 외 8
- Ingenol-3-Angelate Enhances the B Cell Inhibitory Potential of Mesenchymal Stem Cells, Leading to Marked Alleviation of Lupus Symptoms in MRL.faslpr Mice.
International journal of molecular sciences · 2024-11 · Lee HK, Kim HK, Kim JY 외 9
- Corrigendum to "BVN008, Diphtheria-tetanus-acellular pertussis combined vaccine has no effects on fertility and prenatal and postnatal developmental toxicity in female Sprague-Dawley rats" [Reprod. Toxicol. 126 (2024) 108587].
Reproductive toxicology (Elmsford, N.Y.) · 2024-10 · Lee JY, Lee JA, Lee HK 외 3
- Repeated-dose toxicity and toxicokinetic study of isobutylparaben in rats subcutaneously treated for 13 weeks.
Archives of toxicology · 2024-07 · Lee JD, Bae JS, Kim HY 외 4
- BVN008, Diphtheria-tetanus-acellular pertussis combined vaccine has no effects on fertility and prenatal and postnatal developmental toxicity in female Sprague-Dawley rats.
Reproductive toxicology (Elmsford, N.Y.) · 2024-06 · Lee JY, Lee JA, Lee HK 외 3
- Combination of phytochemicals, including ginsenoside and curcumin, shows a synergistic effect on the recovery of radiation-induced toxicity.
PloS one · 2024-01 · Kim MS, Yang SJ, Jung SY 외 6
- Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study.
Frontiers in aging neuroscience · 2023-01 · Nam JY, Chun S, Lee TY 외 13
Patents
KIPRIS · applicant-matchedPublished · 2025-08 · Application 1020250115519
PCT · Published · 2025-08 · Application PCT/KR2025/095500
Published · 2024-12 · Application 1020240198435
Published · 2024-12 · Application 1020240196358
Published · 2024-12 · Application 1020240181201
PCT · Published · 2024-12 · Application PCT/KR2024/020023
Published · 2024-08 · Application 1020240113325
PCT · Published · 2024-08 · Application PCT/KR2024/012615
Published · 2024-08 · Application 1020240103589
PCT · Published · 2024-08 · Application PCT/KR2024/011478
Show 59 more patents
Published · 2024-06 · Application 1020240084574
EP · Published · 2024-06 · Application 24832465.9
PCT · Published · 2024-06 · Application PCT/KR2024/008989
Published · 2023-12 · Application 1020230172636
Registered · 2023-11 · Application 1020230158805
EP · Published · 2023-05 · Application 23807950.3
PCT · Published · 2023-05 · Application PCT/KR2023/006861
Rejected · 2023-02 · Application 1020230017977
US · Published · 2023-02 · Application 18837033
EP · Published · 2023-02 · Application 23753207.2
PCT · Published · 2023-02 · Application PCT/KR2023/001992
Published · 2022-05 · Application 1020220062408
Rejected · 2022-03 · Application 1020220032028
Registered · 2021-08 · Application 1020210111426
US · Published · 2021-08 · Application 18685764
Registered · 2020-12 · Application 1020200177530
Rejected · 2020-12 · Application 1020200176786
Registered · 2020-08 · Application 1020200104535
Rejected · 2020-01 · Application 1020200002758
Rejected · 2019-11 · Application 1020190152353
Registered · 2019-10 · Application 1020190128602
Registered · 2019-10 · Application 1020190122191
Registered · 2019-10 · Application 1020190122192
Registered · 2018-11 · Application 1020180137579
Registered · 2018-11 · Application 1020180137578
Registered · 2018-06 · Application 1020180069263
Registered · 2017-03 · Application 1020170039535
Rejected · 2016-09 · Application 1020160114978
Registered · 2016-02 · Application 1020160023254
Rejected · 2014-07 · Application 1020140097129
Rejected · 2013-11 · Application 1020130142830
Registered · 2012-02 · Application 1020120021449
Rejected · 2012-02 · Application 1020120021411
Rejected · 2010-06 · Application 1020100051907
Registered · 2010-01 · Application 1020100004106
Expired · 2009-10 · Application 1020090099146
Expired · 2009-10 · Application 1020090098965
Rejected · 2008-10 · Application 1020080108036
Expired · 2008-09 · Application 1020080094833
Expired · 2008-09 · Application 1020080094821
Withdrawn · 2007-12 · Application 1020070141414
Expired · 2007-11 · Application 1020070123912
Expired · 2007-11 · Application 1020070123913
Expired · 2007-11 · Application 1020070123914
Expired · 2007-09 · Application 1020070098386
Expired · 2007-04 · Application 1020070038846
Rejected · 2007-02 · Application 1020070011267
Registered · 2006-11 · Application 1020060118370
Rejected · 2006-11 · Application 1020060118358
Rejected · 2006-11 · Application 1020060118381
Expired · 2006-05 · Application 1020060046992
Registered · 2006-04 · Application 1020060036754
Expired · 2005-05 · Application 2020050013542
Expired · 2004-10 · Application 1020040083819
Expired · 2004-10 · Application 1020040083818
Expired · 2004-10 · Application 1020040083820
Expired · 2004-07 · Application 2020040021658
Expired · 2004-07 · Application 1020040059697
Expired · 2004-07 · Application 1020040059698
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot162
- PerplexityPerplexityBot6
- GoogleGoogleOther2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for CORESTEMCHEMON Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded in 2007, SK Innovation is an energy company spanning oil, chemicals, batteries, and LNG, merged with SK E&S in 2024.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition